IL105673A - Use of n-substituted adenosine derivatives for the preparation of medicaments for treating myocardial or cerebral ischemia, certain novel n-substituted adenosine derivatives and pharmaceutical compositions containing them - Google Patents

Use of n-substituted adenosine derivatives for the preparation of medicaments for treating myocardial or cerebral ischemia, certain novel n-substituted adenosine derivatives and pharmaceutical compositions containing them

Info

Publication number
IL105673A
IL105673A IL105673A IL10567393A IL105673A IL 105673 A IL105673 A IL 105673A IL 105673 A IL105673 A IL 105673A IL 10567393 A IL10567393 A IL 10567393A IL 105673 A IL105673 A IL 105673A
Authority
IL
Israel
Prior art keywords
adenosine
chloro
propyl
phenoxy
mmol
Prior art date
Application number
IL105673A
Other languages
English (en)
Other versions
IL105673A0 (en
Original Assignee
Novo Nordisk As
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Novo Nordisk As filed Critical Novo Nordisk As
Publication of IL105673A0 publication Critical patent/IL105673A0/xx
Publication of IL105673A publication Critical patent/IL105673A/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H19/00—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof
    • C07H19/02—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof sharing nitrogen
    • C07H19/04—Heterocyclic radicals containing only nitrogen atoms as ring hetero atom
    • C07H19/16—Purine radicals

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Molecular Biology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Neurosurgery (AREA)
  • Biochemistry (AREA)
  • Biotechnology (AREA)
  • Genetics & Genomics (AREA)
  • Urology & Nephrology (AREA)
  • Epidemiology (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Vascular Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Saccharide Compounds (AREA)
IL105673A 1992-05-14 1993-05-11 Use of n-substituted adenosine derivatives for the preparation of medicaments for treating myocardial or cerebral ischemia, certain novel n-substituted adenosine derivatives and pharmaceutical compositions containing them IL105673A (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
DK92626A DK62692D0 (enrdf_load_stackoverflow) 1992-05-14 1992-05-14

Publications (2)

Publication Number Publication Date
IL105673A0 IL105673A0 (en) 1993-09-22
IL105673A true IL105673A (en) 1998-01-04

Family

ID=8095717

Family Applications (1)

Application Number Title Priority Date Filing Date
IL105673A IL105673A (en) 1992-05-14 1993-05-11 Use of n-substituted adenosine derivatives for the preparation of medicaments for treating myocardial or cerebral ischemia, certain novel n-substituted adenosine derivatives and pharmaceutical compositions containing them

Country Status (9)

Country Link
EP (1) EP0603348A1 (enrdf_load_stackoverflow)
JP (1) JPH06508855A (enrdf_load_stackoverflow)
AU (1) AU671995B2 (enrdf_load_stackoverflow)
CA (1) CA2113547A1 (enrdf_load_stackoverflow)
DK (1) DK62692D0 (enrdf_load_stackoverflow)
FI (1) FI940167L (enrdf_load_stackoverflow)
IL (1) IL105673A (enrdf_load_stackoverflow)
NZ (1) NZ252110A (enrdf_load_stackoverflow)
WO (1) WO1993023418A1 (enrdf_load_stackoverflow)

Families Citing this family (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DK155292D0 (da) * 1992-12-23 1992-12-23 Novo Nordisk As Kemiske forbindelser, deres fremstilling og anvendelse
US5589467A (en) * 1993-09-17 1996-12-31 Novo Nordisk A/S 2,5',N6-trisubstituted adenosine derivatives
PL316985A1 (en) * 1994-05-10 1997-03-03 Sandoz Ltd Derivatives of adenosine
EP0704215A3 (en) * 1994-06-02 1998-04-01 Takeda Chemical Industries, Ltd. Inhibitor of vascular permeability enhancer
GB9421133D0 (en) * 1994-10-20 1994-12-07 Glaxo Group Ltd Medicaments
US6110902A (en) * 1997-06-23 2000-08-29 Moehler; Hanns Method for the inhibition of neuronal activity leading to a focal epileptic seizure by local delivery of adenosine
CO5180581A1 (es) * 1999-09-30 2002-07-30 Pfizer Prod Inc Compuestos para el tratamiento de la isquemia ciones farmaceuticas que los contienen para el tratamiento de la isquemia
US6803457B1 (en) 1999-09-30 2004-10-12 Pfizer, Inc. Compounds for the treatment of ischemia
WO2001087843A1 (en) * 2000-05-15 2001-11-22 Novo Nordisk A/S Compounds for treating disorders where a decreased level of plasma ffa is desired
US7414036B2 (en) 2002-01-25 2008-08-19 Muscagen Limited Compounds useful as A3 adenosine receptor agonists
US20100048501A1 (en) 2006-03-21 2010-02-25 Heinrich-Heine-Universitat Dusseldorf Phosphorylated A2A Receptor Agonists
CZ2009298A3 (cs) * 2009-05-14 2010-11-24 Univerzita Palackého v Olomouci Substituované 6-benzylaminopurin ribosidy, jejich použití a farmaceutický prípravek tyto slouceniny obsahující
WO2011085361A1 (en) 2010-01-11 2011-07-14 Inotek Pharmaceuticals Corporation Combination, kit and method of reducing intraocular pressure
SG184221A1 (en) 2010-03-26 2012-10-30 Inotek Pharmaceuticals Corp Method of reducing intraocular pressure in humans using n6 -cyclopentyladenosine (cpa), cpa derivatives or prodrugs thereof
CN102822188A (zh) * 2010-03-26 2012-12-12 伊诺泰克制药公司 腺苷化合物及其用途
WO2013112850A1 (en) 2012-01-26 2013-08-01 Inotek Pharmaceuticals Corporation Anhydrous polymorphs of (2r,3s,4r,5r)-5-(6-(cyclopentylamino)-9h-purin-9-yl)-3,4-dihydroxytetrahydrofuran-2-yl) } methyl nitrate and processes of preparation thereof
US9522160B2 (en) 2013-03-15 2016-12-20 Inotek Pharmaceuticals Corporation Ophthalmic formulations
JP2015172077A (ja) * 2015-06-24 2015-10-01 中国医学科学院葯物研究所 Ｎ６−置換アデノシン誘導体とｎ６−置換アデニン誘導体の鎮静、催眠、抗うつ、抗痙攣、抗てんかん、抗パーキンソン病と認知証予防・治療の用途
GB2582361A (en) * 2019-03-21 2020-09-23 Univ Warwick Adenosine receptor agonists

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE1670077C3 (de) * 1966-05-07 1975-04-24 Boehringer Mannheim Gmbh, 6800 Mannheim Adenosin-Derivate und Verfahren zu ihrer Herstellung
NL128629C (enrdf_load_stackoverflow) * 1966-05-07
NL6717061A (enrdf_load_stackoverflow) * 1966-12-21 1968-06-24
DE2052596A1 (de) * 1970-10-27 1972-05-04 Boehringer Mannheim Gmbh, 6800 Mannheim Neuartige Verwendung von N(6)-substituierten Adenosin-Derivaten
DE3406533A1 (de) * 1984-02-23 1985-08-29 Boehringer Mannheim Gmbh, 6800 Mannheim Verwendung von adenosin-derivaten als antiallergica und arzneimittel, die diese enthalten
EP0305643B1 (en) * 1984-04-18 1994-01-05 Whitby Research Incorporated N-6 thienyl substituted adenosine derivatives as cardiac vasodilators
US4791103A (en) * 1985-02-08 1988-12-13 Warner-Lambert Company 2,N6 -disubstituted adenosines, derivatives and methods of use
JPH0696534B2 (ja) * 1986-04-25 1994-11-30 ヘキストジヤパン株式会社 抗痴呆剤
GB8729994D0 (en) * 1987-12-23 1988-02-03 Glaxo Group Ltd Chemical compounds
HUT61567A (en) * 1990-12-07 1993-01-28 Sandoz Ag Process for producing new pharmaceutical compositions comprising 2'-o-alkyladenosine derivatives and for producing 6-cyclohexyl-2'-o-methyladenosinehydrate
DK62592D0 (enrdf_load_stackoverflow) * 1992-05-14 1992-05-14 Novo Nordisk As

Also Published As

Publication number Publication date
IL105673A0 (en) 1993-09-22
CA2113547A1 (en) 1993-11-25
DK62692D0 (enrdf_load_stackoverflow) 1992-05-14
AU4061293A (en) 1993-12-13
FI940167A7 (fi) 1994-03-03
WO1993023418A1 (en) 1993-11-25
AU671995B2 (en) 1996-09-19
EP0603348A1 (en) 1994-06-29
FI940167L (fi) 1994-03-03
FI940167A0 (fi) 1994-01-13
JPH06508855A (ja) 1994-10-06
NZ252110A (en) 1996-07-26

Similar Documents

Publication Publication Date Title
IL105673A (en) Use of n-substituted adenosine derivatives for the preparation of medicaments for treating myocardial or cerebral ischemia, certain novel n-substituted adenosine derivatives and pharmaceutical compositions containing them
US5589467A (en) 2,5',N6-trisubstituted adenosine derivatives
RU2157215C2 (ru) Способ лечения инфекций, вызываемых вирусом гепатита в
CZ20021223A3 (cs) Purinové deriváty
US5578582A (en) Methods of treating ischemia with C2, N6 -disubstituted adenosine derivatives
CZ20014397A3 (cs) Deriváty purinu
JP2003532643A (ja) 肝炎ウイルス感染症を治療するための３’−または２’−ヒドロキシメチル置換ヌクレオシド誘導体
AU2001230913A1 (en) Methanocarba cycloalkyl nucleoside analogues
US5430027A (en) 2-chloro-N6 -substituted adenosines, their pharmaceutical compositions, and activity in treating ischemias
US5484774A (en) 2, N6 -disubstituted adenosines, tri-O-ester derivatives and their pharmaceutical compositions to treat ischemias
JP2954971B2 (ja) 選択的アデノシン受容体剤
US5683989A (en) Treatment of ischemias by administration of 2,N6 -substituted adenosines
US5672588A (en) Purine derivatives

Legal Events

Date Code Title Description
FF Patent granted
KB Patent renewed
RH Patent void